NEUROCRINE BIOSCIENCES, INC.
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 1992-01-01
- Employees
- 1.4K
- Market Cap
- $15.4B
- Website
- http://www.neurocrine.com
A Study to Evaluate NBI-6024 in Adult and Adolescent Patients With New Onset of Type 1 Diabetes Mellitus
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2009-04-01
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 188
- Registration Number
- NCT00873561
- Locations
- 🇨🇿
University Hospital and School of Medicine, Olomouc, Czech Republic
🇨🇿Faculty Hospital Motol, Prague, Czech Republic
🇫🇮Helsinki University Hospital, Helsinki, Finland
An Exploratory Study of NBI-34060 Capsules and Next Day Functioning
Phase 3
Withdrawn
- Conditions
- Insomnia
- First Posted Date
- 2007-09-06
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Neurocrine Biosciences
- Registration Number
- NCT00525941
- Locations
- 🇺🇸
Sleep Disorders Center of Georgia, Atlanta, Georgia, United States
🇺🇸Clinilabs, Inc., New York, New York, United States
🇺🇸Tri-State Sleep Disorders Center, Cincinnati, Ohio, United States
Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression
Phase 3
Terminated
- Conditions
- InsomniaDepression
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2007-10-02
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 380
- Registration Number
- NCT00232167
Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS)
Phase 2
Completed
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2008-03-21
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 150
- Registration Number
- NCT00079495
NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma Multiforme
Phase 2
Completed
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-11-13
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Neurocrine Biosciences
- Registration Number
- NCT00014677
- Locations
- 🇺🇸
Charlotte Neurosurgical Associates, Charlotte, North Carolina, United States
🇺🇸UCSD Thornton Hospital, La Jolla, California, United States
🇺🇸Emory University Hospital - Atlanta, Atlanta, Georgia, United States
Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer
Phase 1
Completed
- Conditions
- Kidney CancerBreast CancerLung Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Neurocrine Biosciences
- Registration Number
- NCT00039052
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
© Copyright 2025. All Rights Reserved by MedPath